Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Main Authors: Zhu, Yuan Xiao, Shi, Chang-Xin, Bruins, Laura A., Wang, Xuewei, Riggs, Daniel L., Porter, Brooke, Ahmann, Jonathan M., de Campos, Cecilia Bonolo, Braggio, Esteban, Bergsagel, P. Leif, Stewart, A. Keith
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6370766/
https://ncbi.nlm.nih.gov/pubmed/30741931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0173-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares